Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. 

The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's current 150kV superficial system, including built-in dosimetry control, filter and applicator recognition and suitability for use with oval applicators. The energy range of the new Xstrahl 150 means that superficial lesions can be successfully treated from basal cell carcinoma and squamous cell carcinoma to keloid scars and dermatological conditions such as psoriasis.

"We've re-engineered the capabilities of our 150kV offering for skin cancer treatments," says Adrian Treverton, Xstrahl Group CEO, in a news release.  "The result is a one-stop-shop for all non-melanoma skin cancer cases, with optimum levels of dose control."

The new Xstrahl 150 system also offers enhanced maneuverability. The range and flexibility of movement in the treatment arm enables smooth adjustment and easy set up for each treatment field, while also ensuring patient comfort. The new Xstrahl 150 can be floor or ceiling mounted, making it easy to install alongside other equipment and adaptable where space is restricted.